Now showing items 1-20 of 67

    • Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. 

      James, ND; de Bono, JS; Spears, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Ritchie, AWS; Amos, CL; Gilson, C; Jones, RJ; Matheson, D; Millman, R; Attard, G; Chowdhury, S; Cross, WR; Gillessen, S; Parker, CC; Russell, JM; Berthold, DR; Brawley, C; Adab, F; Aung, S; Birtle, AJ; Bowen, J; Brock, S; Chakraborti, P; Ferguson, C; Gale, J; Gray, E; Hingorani, M; Hoskin, PJ; Lester, JF; Malik, ZI; McKinna, F; McPhail, N; Money-Kyrle, J; O'Sullivan, J; Parikh, O; Protheroe, A; Robinson, A; Srihari, NN; Thomas, C; Wagstaff, J; Wylie, J; Zarkar, A; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-07)
      <h4>Background</h4>Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer. We assessed the effect of this combination in men starting long-term androgen-deprivation therapy (ADT), using ...
    • Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. 

      Hoyle, AP; Ali, A; James, ND; Cook, A; Parker, CC; de Bono, JS; Attard, G; Chowdhury, S; Cross, WR; Dearnaley, DP; Brawley, CD; Gilson, C; Ingleby, F; Gillessen, S; Aebersold, DM; Jones, RJ; Matheson, D; Millman, R; Mason, MD; Ritchie, AWS; Russell, M; Douis, H; Parmar, MKB; Sydes, MR; Clarke, NW; STAMPEDE Investigators
      <h4>Background</h4>Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen ...
    • Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

      Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, W; Gillessen, S; Malik, ZI; Jones, R; Parker, CC; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, DC; Hughes, R; McLaren, D; Lester, JF; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND; STAMPEDE Investigators (2018-05)
      <h4>Background</h4>Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy for advanced or metastatic prostate cancer: ...
    • Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. 

      Mason, MD; Clarke, NW; James, ND; Dearnaley, DP; Spears, MR; Ritchie, AWS; Attard, G; Cross, W; Jones, RJ; Parker, CC; Russell, JM; Thalmann, GN; Schiavone, F; Cassoly, E; Matheson, D; Millman, R; Rentsch, CA; Barber, J; Gilson, C; Ibrahim, A; Logue, J; Lydon, A; Nikapota, AD; O'Sullivan, JM; Porfiri, E; Protheroe, A; Srihari, NN; Tsang, D; Wagstaff, J; Wallace, J; Walmsley, C; Parmar, MKB; Sydes, MR; STAMPEDE Investigators (2017-05)
      Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally ...
    • Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. 

      Woods, BS; Sideris, E; Sydes, MR; Gannon, MR; Parmar, MKB; Alzouebi, M; Attard, G; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, PR; Cook, A; Cross, WR; Dearnaley, DP; Gale, J; Gibbs, S; Graham, JD; Hughes, R; Jones, RJ; Laing, R; Mason, MD; Matheson, D; McLaren, DB; Millman, R; O'Sullivan, JM; Parikh, O; Parker, CC; Peedell, C; Protheroe, A; Ritchie, AWS; Robinson, A; Russell, JM; Simms, MS; Srihari, NN; Srinivasan, R; Staffurth, JN; Sundar, S; Thalmann, GN; Tolan, S; Tran, ATH; Tsang, D; Wagstaff, J; James, ND; Sculpher, MJ (2018-12)
      <h4>Background</h4>Results from large randomised controlled trials have shown that adding docetaxel to the standard of care (SOC) for men initiating hormone therapy for prostate cancer (PC) prolongs survival for those with ...
    • Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. 

      Clarke, NW; Ali, A; Ingleby, FC; Hoyle, A; Amos, CL; Attard, G; Brawley, CD; Calvert, J; Chowdhury, S; Cook, A; Cross, W; Dearnaley, DP; Douis, H; Gilbert, D; Gillessen, S; Jones, RJ; Langley, RE; MacNair, A; Malik, Z; Mason, MD; Matheson, D; Millman, R; Parker, CC; Ritchie, AWS; Rush, H; Russell, JM; Brown, J; Beesley, S; Birtle, A; Capaldi, L; Gale, J; Gibbs, S; Lydon, A; Nikapota, A; Omlin, A; O'Sullivan, JM; Parikh, O; Protheroe, A; Rudman, S; Srihari, NN; Simms, M; Tanguay, JS; Tolan, S; Wagstaff, J; Wallace, J; Wylie, J; Zarkar, A; Sydes, MR; Parmar, MKB; James, ND (2019-12)
      <h4>Background</h4>STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. ...
    • Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. 

      James, ND; Sydes, MR; Clarke, NW; Mason, MD; Dearnaley, DP; Spears, MR; Ritchie, AWS; Parker, CC; Russell, JM; Attard, G; de Bono, J; Cross, W; Jones, RJ; Thalmann, G; Amos, C; Matheson, D; Millman, R; Alzouebi, M; Beesley, S; Birtle, AJ; Brock, S; Cathomas, R; Chakraborti, P; Chowdhury, S; Cook, A; Elliott, T; Gale, J; Gibbs, S; Graham, JD; Hetherington, J; Hughes, R; Laing, R; McKinna, F; McLaren, DB; O'Sullivan, JM; Parikh, O; Peedell, C; Protheroe, A; Robinson, AJ; Srihari, N; Srinivasan, R; Staffurth, J; Sundar, S; Tolan, S; Tsang, D; Wagstaff, J; Parmar, MKB; STAMPEDE investigators (2016-03)
      <h4>Background</h4>Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits ...
    • Bone lesion absorbed dose profiles in patients with metastatic prostate cancer treated with molecular radiotherapy. 

      Denis-Bacelar, AM; Chittenden, SJ; McCready, VR; Divoli, A; Dearnaley, DP; O'Sullivan, JM; Johnson, B; Flux, GD (2018-04)
      OBJECTIVE:The aim of this study was to calculate the range of absorbed doses that could potentially be delivered by a variety of radiopharmaceuticals and typical fixed administered activities used for bone pain palliation ...
    • Clinical Outcomes of Image Guided Adaptive Hypofractionated Weekly Radiation Therapy for Bladder Cancer in Patients Unsuitable for Radical Treatment. 

      Hafeez, S; McDonald, F; Lalondrelle, S; McNair, H; Warren-Oseni, K; Jones, K; Harris, V; Taylor, H; Khoo, V; Thomas, K; Hansen, V; Dearnaley, D; Horwich, A; Huddart, R (2017-05)
      <h4>Purpose and objectives</h4>We report on the clinical outcomes of a phase 2 study assessing image guided hypofractionated weekly radiation therapy in bladder cancer patients unsuitable for radical treatment.<h4>Methods ...
    • Common genetic variation associated with increased susceptibility to prostate cancer does not increase risk of radiotherapy toxicity. 

      Ahmed, M; Dorling, L; Kerns, S; Fachal, L; Elliott, R; Partliament, M; Rosenstein, BS; Vega, A; Gómez-Caamaño, A; Barnett, G; Dearnaley, DP; Hall, E; Sydes, M; Burnet, N; Pharoah, PDP; Eeles, R; West, CML (2016-05)
      <h4>Background</h4>Numerous germline single-nucleotide polymorphisms increase susceptibility to prostate cancer, some lying near genes involved in cellular radiation response. This study investigated whether prostate cancer ...
    • Derivation of dose/volume constraints for the anorectum from clinician and patient-reported outcomes in the CHHiP trial of radiotherapy fractionation. 

      Wilkins, A; Naismith, O; Brand, D; Fernandez, K; Hall, E; Dearnaley, D; Gulliford, S; CHHiP Trial Management Group (2020-01-24)
      BACKGROUND:The CHHiP trial randomised 3216 men with localised prostate cancer (1:1:1) to three radiotherapy fractionation schedules: 74Gy/37 fractions (f) over 7.4 weeks, 60Gy/20f/4 weeks and 57Gy/19f/3.8 weeks. Literature-based ...
    • Dietary fat and early-onset prostate cancer risk. 

      Lophatananon, A; Archer, J; Easton, D; Pocock, R; Dearnaley, D; Guy, M; Kote-Jarai, Z; O'Brien, L; Wilkinson, RA; Hall, AL; Sawyer, E; Page, E; Liu, J-F; Barratt, S; Rahman, AA; UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; Eeles, R; Muir, K (2010-05)
      The UK incidence of prostate cancer has been increasing in men aged < 60 years. Migrant studies and global and secular variation in incidence suggest that modifiable factors, including a high-fat diet, may contribute to ...
    • Diethylstilbestrol in castration-resistant prostate cancer. 

      Wilkins, A; Shahidi, M; Parker, C; Gunapala, R; Thomas, K; Huddart, R; Horwich, A; Dearnaley, D (2012-12)
      <h4>Unlabelled</h4>What's known on the subject? and What does the study add? Diethylstilbestrol (DES) was the first hormone treatment used for prostate cancer and has also shown effectiveness in castration-resistant disease ...
    • Dosimetry and Gastrointestinal Toxicity Relationships in a Phase II Trial of Pelvic Lymph Node Radiotherapy in Advanced Localised Prostate Cancer. 

      Ferreira, MR; Thomas, K; Truelove, L; Khan, A; Parker, C; Dearnaley, DP; Gulliford, S (2019-06)
      AIMS:Pelvic lymph node (PLN) radiotherapy for high-risk prostate cancer is limited by late gastrointestinal toxicity. Application of rectal and bowel constraints may reduce risks of side-effects. We evaluated associations ...
    • Effect of Dose to the Penile Bulb on Erectile Potency (EP) in Prostate Image-guided Radiotherapy (IGRT) 

      Murray, J; Dean, J; Mossop, H; Hall, E; Dearnaley, D; Gulliford, S (ELSEVIER SCIENCE LONDON, 2017-03-01)
    • Effect on Overall Survival of Locoregional Treatment in a Cohort of De Novo Metastatic Prostate Cancer Patients: A Single Institution Retrospective Analysis From the Royal Marsden Hospital. 

      Bianchini, D; Lorente, D; Rescigno, P; Zafeiriou, Z; Psychopaida, E; O'Sullivan, H; Alaras, M; Kolinsky, M; Sumanasuriya, S; Sousa Fontes, M; Mateo, J; Perez Lopez, R; Tunariu, N; Fotiadis, N; Kumar, P; Tree, A; Van As, N; Khoo, V; Parker, C; Eeles, R; Thompson, A; Dearnaley, D; de Bono, JS (2017-10)
      <h4>Background</h4>The optimal management of the primary tumor in metastatic at diagnosis (M1) prostate cancer (PCa) patients is not yet established. We retrospectively evaluated the effect of locoregional treatment (LRT) ...
    • Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. 

      Venkitaraman, R; Thomas, K; Huddart, RA; Horwich, A; Dearnaley, DP; Parker, CC (2008-02)
      <h4>Objective</h4>To evaluate the prostate-specific antigen (PSA) response rate and duration of PSA response to dexamethasone in patients with castration-refractory prostate cancer (CRPC), as corticosteroids are frequently ...
    • Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. 

      Dearnaley, DP; Jovic, G; Syndikus, I; Khoo, V; Cowan, RA; Graham, JD; Aird, EG; Bottomley, D; Huddart, RA; Jose, CC; Matthews, JHL; Millar, JL; Murphy, C; Russell, JM; Scrase, CD; Parmar, MKB; Sydes, MR (2014-04)
      <h4>Background</h4>The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years ...
    • Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP trial. 

      Brand, DH; Brüningk, SC; Wilkins, A; Fernandez, K; Naismith, O; Gao, A; Syndikus, I; Dearnaley, DP; Tree, AC; van As, N; Hall, E; Gulliford, S; CHHiP Trial Management Group (2021-01-04)
      <h4>Purpose</h4>Changes in fraction size of external beam radiotherapy (EBRT) exert non-linear impacts on subsequent toxicity. Commonly described by the linear-quadratic model, fraction size sensitivity of normal tissues ...
    • Evaluation of a multi-atlas CT synthesis approach for MRI-only radiotherapy treatment planning. 

      Guerreiro, F; Burgos, N; Dunlop, A; Wong, K; Petkar, I; Nutting, C; Harrington, K; Bhide, S; Newbold, K; Dearnaley, D; deSouza, NM; Morgan, VA; McClelland, J; Nill, S; Cardoso, MJ; Ourselin, S; Oelfke, U; Knopf, AC (2017-03)
      <h4>Background and purpose</h4>Computed tomography (CT) imaging is the current gold standard for radiotherapy treatment planning (RTP). The establishment of a magnetic resonance imaging (MRI) only RTP workflow requires the ...